SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-023323
Filing Date
2021-05-04
Accepted
2021-05-04 16:05:43
Documents
14
Period of Report
2021-05-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K arwr-8k_20210504.htm   iXBRL 8-K 38739
2 EX-99.1 arwr-ex991_6.htm EX-99.1 227948
3 GRAPHIC gxds1eev1f5s000001.jpg GRAPHIC 49974
  Complete submission text file 0001564590-21-023323.txt   477108

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA arwr-20210504.xsd EX-101.SCH 5812
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE arwr-20210504_lab.xml EX-101.LAB 19478
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE arwr-20210504_pre.xml EX-101.PRE 11657
7 EXTRACTED XBRL INSTANCE DOCUMENT arwr-8k_20210504_htm.xml XML 3565
Mailing Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105
Business Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105 626-696-4702
ARROWHEAD PHARMACEUTICALS, INC. (Filer) CIK: 0000879407 (see all company filings)

IRS No.: 460408024 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38042 | Film No.: 21888381
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences